Wells Fargo’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-4,620
| Closed | -$81K | – | 8279 |
|
|
2021
Q3 | $81K | Sell |
4,620
-13,028
| -74% | -$152K | ﹤0.01% | 5467 |
|
|
2021
Q2 | $172K | Sell |
17,648
-1,625
| -8% | -$15.3K | ﹤0.01% | 5090 |
|
|
2021
Q1 | $206K | Buy |
19,273
+4,580
| +31% | +$56.6K | ﹤0.01% | 5136 |
|
|
2020
Q4 | $216K | Buy |
14,693
+725
| +5% | +$10.5K | ﹤0.01% | 5042 |
|
|
2020
Q3 | $198K | Buy |
13,968
+8,968
| +179% | +$89.4K | ﹤0.01% | 4971 |
|
|
2020
Q2 | $40K | Buy |
5,000
+1,700
| +52% | +$10.5K | ﹤0.01% | 5548 |
|
|
2020
Q1 | $13K | Sell |
3,300
-7,300
| -69% | -$27.6K | ﹤0.01% | 5705 |
|
|
2019
Q4 | $11K | Buy |
10,600
+4,250
| +67% | +$1.63K | ﹤0.01% | 5884 |
|
|
2019
Q3 | $2K | Sell |
6,350
-1,500
| -19% | -$507 | ﹤0.01% | 6233 |
|
|
2019
Q2 | $3K | Sell |
7,850
-2,750
| -26% | -$1.42K | ﹤0.01% | 6142 |
|
|
2019
Q1 | $7K | Sell |
10,600
-600
| -5% | -$733 | ﹤0.01% | 5695 |
|
|
2018
Q4 | $19K | Sell |
11,200
-21,289
| -66% | -$63.9K | ﹤0.01% | 5795 |
|
|
2018
Q3 | $189K | Sell |
32,489
-3,150
| -9% | -$17.8K | ﹤0.01% | 5038 |
|
|
2018
Q2 | $214K | Buy |
35,639
+9,379
| +36% | +$59.8K | ﹤0.01% | 4995 |
|
|
2018
Q1 | $189K | Buy |
26,260
+160
| +0.6% | +$1.21K | ﹤0.01% | 5013 |
|
|
2017
Q4 | $189K | Buy |
26,100
+9,550
| +58% | +$79.1K | ﹤0.01% | 4982 |
|
|
2017
Q3 | $85K | Buy |
16,550
+1,000
| +6% | +$4.7K | ﹤0.01% | 5295 |
|
|
2017
Q2 | $69K | Sell |
15,550
-2,150
| -12% | -$11.9K | ﹤0.01% | 5309 |
|
|
2017
Q1 | $109K | Buy |
17,700
+4,500
| +34% | +$26.4K | ﹤0.01% | 5159 |
|
|
2016
Q4 | $75K | Buy |
13,200
+1,400
| +12% | +$13.9K | ﹤0.01% | 5270 |
|
|
2016
Q3 | $175K | Buy |
11,800
+10,800
| +1,080% | +$124K | ﹤0.01% | 4557 |
|
|
2016
Q2 | $9K | Hold |
1,000
| – | – | ﹤0.01% | 5703 |
|
|
2016
Q1 | $9K | Hold |
1,000
| – | – | ﹤0.01% | 5738 |
|
|
2015
Q4 | $13K | Hold |
1,000
| – | – | ﹤0.01% | 5682 |
|
|
2015
Q3 | $13K | Buy |
+1,000
| New | +$18.4K | ﹤0.01% | 5663 |
|
Other funds holding TRIL
Wells Fargo's TRIL Position: Q4 2021 in Review
Wells Fargo sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 4,620 shares — an estimated $81K sold.
Wells Fargo first reported a position in TRIL in Q3 2015 and held it in 25 quarters. The position peaked at $216K in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Wells Fargo reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Wells Fargo sold 4,620 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $81K.
- Wells Fargo first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 25 quarters.
- Wells Fargo's Trillium Therapeutics Inc. position peaked at $216K in Q4 2020.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Wells Fargo's 13F filing for Q4 2021, filed 14 Feb 2022.